Clinical Trial Update: Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating metformin to prevent androgen deprivation therapy-induced insulin resistance and metabolic syndrome. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Metabolic Syndrome

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Western Sydney Local Health District | Conditions: Metabolic Syndrome, Hypercholesterolemia | Phase 2 | Status: COMPLETED